Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleAntiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.
Author(s)Orr LE, McKernan JF, Bloome B
Journal, Volume, IssueAnnals of Internal Medicine 1980;140(11):1431-1433
Major outcome(s)no nausea and no vomiting (complete response) in 73% (40/55 courses) in THC group
IndicationCancer chemotherapy; Nausea/vomitingAbstract

Fifty-five patients harboring a variety of neoplasms and previously found to have severe nausea or emesis from antitumor drugs were given antiemetic prophylaxis in a double-blind, randomized, crossover fashion. Tetrahydrocannabinol (THC), prochlorperazine, and placebo were compared. Nausea was absent in 40 of 55 patients receiving THC, eight of 55 patients receiving prochlorperazine, and five of 55 in the placebo group. The antiemetic effect of THC appeared to be more efficacious for cyclophosphamide, fluorouracil, and doxorubicin hydrochloride, and less so for mechlorethamine hydrochloride and the nitrosureas. Tetrahydrocannabinol appears to offer significant control of nausea in most patients and exceeding by far that provided by prochlorperazine.

Dose(s)4 x 7 mg/m2 every 4 hours
Duration (days)several days
Participants55 cancer patients
DesignControlled study
Type of publication
Address of author(s)Medical Oncology Section, Southern California Cancer Center, California Hosp. Medical Center, Los Angeles, California, USA
Full text

[Back to Overview]  [IACM Homepage]